The Antidote: Inside the World of New Pharma (70 page)

(
pp. 214
–17) Interviews with Matt Emmens, Christopher Wright, Mark Namchuk, and Josh Boger. The Emmens/Huckman interview can be viewed online at
www.cnbc.com/id/34845387
. David Kirkpatrick, “White House Affirms Deal on Drug Cost,”
New York Times
, August 6, 2009; Aelok Mehta, “Seizures, Epilepsy Linked to Immune Reaction,”
The Dana Foundation
, April 2009.

(
pp. 217
–20) Interviews with Nancy Wysenski and Matt Emmens. Michael Cooper, “GOP Senate Victory Stuns Democrats,”
New York Times
, January 21, 2010; David D. Kirkpatrick, “White House Affirms Deal on Drug Cost,”
New York Times
, August 6, 2009; Sheryl Gay Stolberg and Robert Pear, “Obama Signs Health Care Overhaul Bill, with a Flourish,”
New York Times
, March 23, 2010.

(
pp. 220
–24) Interviews with Bob Kauffman and Jack Weet. Luke Timmerman, “Vertex Maps Out Combo Drug Game Plan for Treating Hepatitis C,” Xconomy, March 8, 2010; Andrew Pollack, “Hepatitis C Drug Raises Cure Rate in Late Trial,”
New York Times
, May 25, 2010.

(
pp. 224
–29) Interviews with Bo Cumbo, Jack Weet, Bob Kauffman, and Matt Emmens.

(
pp. 229
–33) Interviews with Bo Cumbo, Jack Weet, Peter Mueller, Bob Kauffman, and Matt Emmens. Robert Weisman, “Vertex Seeks Fast Approval for Drug,”
Boston Globe
, November 24, 2010; “Vertex Seeks FDA Green Light for Hepatitis C Drug: Chomps at the Bit for Fast Review,” Xconomy, November 23, 2010.

(
pp. 237
–39) Interviews with Matt Emmens and Jack Weet. Ed Silverman, “JPMorgan Event: Narrow Hallways and Velvet Ropes,”
Pharmalot.com
, January 14, 2011; Mike Huckman, “Vertex Adds Color to the JPMorgan Healthcare Conference,”
CNBC.com
, January 13, 2011; Adam Feuerstein, “Merck Beats Vertex to FDA Hep C Filing,” TheStreet, January 6, 2011; Thomas Gryta, “Vertex CEO Unfazed by Matchup Against Merck,”
Wall Street Journal
, January 10, 2011; Julie M. Donnelly,“Vertex Gears Up for Its Big Year,”
Boston Business Journal
, December 31, 2010.

(
pp. 239
–41) Interviews with John Condon and Jack Weet. Casey Ross, “City Draws Cambridge Drug Firm to Fan Pier,”
Boston Globe
, January 25, 2011; Jerry Kronenberg, “Cambridge Prepares Counter-Bid to Keep Vertex Away from Hub,”
Boston Herald
, February 14, 2011.

(
pp. 241
–43) Interviews with Bo Cumbo and Josh Boger.

(
pp. 243
–44) Interviews with Megan Pace, Peter Mueller, Jack Weet, Bob Kauffman, Ken Boger, and Josh Boger.

(
pp. 244
–47) Christopher K. Hepp, “New Merck CEO Kenneth C. Frazier Has Philadelphia Roots,”
Philly.com
, December 1, 2010; Linda A. Johnson, “Earnings Preview: Merck to Tout Pipeline in Report,”
BloombergBusinessweek
, February 2, 2011; Tom Randall, “Merck’s Risky Bet on Research,”
BloombergBusinessweek
, April 23, 2011; Tom Randall, “Merck, Pfizer Research Strategies Diverge on Spending,”
Bloomberg
, February 3, 2011; “Pfizer vs. Merck and the Future of R&D: Déjà Vu All Over Again,
INVIVO
, February 10, 2011; “Goldman Sachs Is Bullish on Vertex,”
Bloomberg News
, February 9, 2011.

(
pp. 247
–51) Interviews with Peter Mueller, Ian Smith, Ken Boger, Bob Kauffman, Matt Emmens, Geoff Porges, and Eric Olson. Andrew Pollack, “Trial Shows Cystic Fibrosis Drug Helped Ease Breathing,”
New York Times
, February 23, 2011; Luke Timmerman, “Vertex Nails Pivotal Study for Cystic Fibrosis, Racing Toward Market with Second Drug,” Xconomy, February 23, 2011; Matthew Herper, “Vertex May Make History with Cystic Fibrosis Drug,”
Forbes
, February 23, 2011; Matthew Herper, “A Big and Dangerous Day for Personalized Medicine,”
Forbes
, February 23, 2011.

(
pp. 252
–55) Interview with Keith Johnson.